| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1930-05-19 |
| Identifiers | MRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158 |
| Document date | 1963-10-21 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit, on day 10 of the first cycle of chemotherapy after surgery. [S]
Ms. Hansberry, now 33, comes for her yearly preventive visit on day 10 of the first cycle of fluorouracil, leucovorin and irinotecan after her pancreaticoduodenectomy. The cycle went well: one day of nausea settled with olanzapine, two loose stools on day 4 controlled with loperamide, and no fever. She takes pancrelipase three capsules with meals and two with snacks, and her stools are formed. Insulin glargine is 10 units at night; fasting readings are 110 to 140 mg/dL with no low readings. She takes apixaban twice a day without bleeding. The tingling in her fingers in the cold is fading now that oxaliplatin has stopped. She writes most mornings and has finished a draft of the new play's second act. Her PHQ-9 today is 5. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 33 |
| Active conditions | Pancreatic adenocarcinoma after six cycles of modified FOLFIRINOX and pancreaticoduodenectomy (R0); on chemotherapy after surgery; diabetes due to pancreatic disease on insulin; exocrine pancreatic insufficiency on pancrelipase |
| Medicines | Fluorouracil, leucovorin and irinotecan every two weeks; pegfilgrastim; apixaban 2.5 mg twice daily; insulin glargine 10 units; pancrelipase; pantoprazole; olanzapine, ondansetron and loperamide as needed; oxycodone rarely |
| Mood | PHQ-9 5 |
Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchetti-Fields. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than before surgery |
| Psychosocial | Close friends and fellow writers visit and drive her to treatment; worry about the cancer returning; writing gives her purpose |
| Tobacco | Never smoked |
| Alcohol and drugs | No alcohol since diagnosis; no drugs |
| Physical activity | Walks 20 minutes by the river most days |
| Nutrition | Five small meals a day with pancrelipase; weight steady since surgery; follows the dietitian's plan |
| Sleep | Seven hours, broken on the nights after chemotherapy |
| Sexual and reproductive health | Not sexually active now; would use condoms and talk to the clinic first; does not want a pregnancy during or soon after treatment |
| Safety at home | Feels safe; no one hurts, threatens, or controls her; no firearm in the home |
| Road safety | Wears a seat belt; friends drive her on treatment days |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for two days after each cycle; no fever, night sweats or weight loss since surgery |
| Eyes | Negative | No vision change; dilated eye examination last week normal |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Nausea for one day and two loose stools after the cycle; stools otherwise formed; no abdominal pain or yellow eyes |
| Genitourinary | Negative | No urinary symptoms; periods irregular since chemotherapy |
| Breast | Negative | No lump or nipple discharge |
| Musculoskeletal | Negative | No joint or bone pain |
| Integumentary | Negative | Hair thinning; incision healed |
| Neurological | Positive | Tingling in the fingertips in the cold, fading |
| Endocrine | Negative | No low glucose readings |
| Hematologic and lymphatic | Negative | No bruising or bleeding on apixaban |
| Psychiatric | Negative | Mood fair; PHQ-9 5; no thoughts of self-harm |
14 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 1963-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 1963-04-24 to 1963-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 1963-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 1963-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 1963-05-04 to 1963-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 1963-05-18 to 1963-07-13 | completed | S |
| Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6 | Day 1 of cycle 6 | Intravenous route | 1963-07-27 to 1963-07-27 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 1963-05-18 to 1963-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 1963-05-20 to 1963-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 1963-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 1963-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 1963-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 1963-06-29 to 1963-08-21 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days | 40 mEq today, then 20 mEq daily for three days | Oral route | 1963-07-16 to 1963-07-19 | completed | S |
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg once daily for 28 days | Subcutaneous route | 1963-08-24 to 1963-09-21 | completed | S |
| Insulin glargine 100 units/mL pen, 8 units under the skin at night | 8 units at night | Subcutaneous route | 1963-08-28 to 1963-10-05 | completed | S |
| Insulin glargine 100 units/mL pen, 10 units under the skin at night | 10 units at night | Subcutaneous route | 1963-10-05 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack | Three capsules with each meal, two with each snack | Oral route | 1963-10-05 | active | S |
| Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery | Day 1 every 14 days for six cycles | Intravenous route | 1963-10-12 | active | S |
| Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery | Day 1 every 14 days for six cycles | Intravenous route | 1963-10-12 | active | S |
| Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 1963-10-12 | active | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery | 6 mg on day 3 of each cycle | Subcutaneous route | 1963-10-14 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgery | One tablet twice daily | Oral route | 1963-10-12 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1963-10-21 | Body height | 163 | cm | S |
| 1963-10-21 | Body weight | 52.4 | kg | S |
| 1963-10-21 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 1963-10-21 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1963-10-21 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1963-10-21 | Heart rate | 84 | /min | S |
| 1963-10-21 | Respiratory rate | 14 | /min | S |
| 1963-10-21 | Body temperature | 36.6 | Cel | S |
| 1963-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1963-10-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 1963-10-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 52.4 kg, BMI 19.7; blood pressure 106/66 |
| Head, eyes, ears, nose, and throat | No mouth sores; no scleral icterus |
| Neck | No lymph nodes; thyroid normal |
| Breasts | Examined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Healed upper midline and right subcostal incision; soft, non-tender; no mass, no fluid |
| Skin | Port site clean; no rash or bruising |
| Feet | Monofilament sensation normal; pulses present; no lesions |
| Neurological | Light touch slightly reduced at the fingertips; vibration and reflexes normal; steady gait |
| Psychiatric | Thoughtful, wry and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | resolved | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolved | resolved | confirmed | K52.1 | S — Synthetic treatment effect; not a historical claim. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
| After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetes | active | confirmed | Z90.411 | S — Synthetic consequence of the synthetic operation. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 106/66 mmHg |
| Depression screening | Completed today | PHQ-9 score 5; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | No alcohol since diagnosis |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Cervical cancer screening | Due | Due (last test four years ago, normal); HPV test planned after chemotherapy ends, at her choice |
| Breast cancer screening | Not indicated | Screening mammography starts at 40; no family history of breast or ovarian cancer; germline panel negative |
| Colorectal cancer screening | Not indicated | Starts at 45; germline panel negative for Lynch syndrome genes |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before chemotherapy; hepatitis B surface antibody negative |
| Diabetes care: A1c, eye and foot examination, urine albumin | Up to date | A1c 7.0% in August; dilated eye examination last week normal; foot examination today normal; urine albumin-to-creatinine ratio normal at the visit after surgery |
| Lipid screening | Due | Recommended for adults with diabetes; with the next blood tests |
| Influenza vaccine | Completed today | Inactivated vaccine given between cycles |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine given |
| Pneumococcal vaccine | Up to date | PCV20 before chemotherapy |
| Recombinant zoster vaccine | Up to date | Two doses, before and during chemotherapy, for an adult on immunosuppressive treatment |
| Hepatitis B vaccine | Due | Surface antibody negative; series after chemotherapy ends |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap four years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune from childhood doses; live vaccines are avoided during chemotherapy |
| Contraception counseling | Completed today | No estrogen because of clot risk; condoms for now; IUD offered for later |
| Dental examination | Due | Cleaning between cycles when counts are recovered |
Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula [S]
Guideline basis: Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Cycle 2 in five days. Cervical screening and the hepatitis B vaccine series after chemotherapy. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 30 minutes, with her consent, building on her conversations with the palliative care team. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care proxy form. She said that she wants to be told everything about her illness directly and in plain words, never through someone else; that she wants all treatment that has a real chance of controlling the cancer, as long as she can think clearly and write; and that if the cancer returns and can no longer be controlled, she would want care focused on comfort and on time at her desk and with her friends, at home if possible, rather than intensive care. She asked that her pain be treated fully even if it makes her sleepier near the end. To be revisited at each change in her health and at least yearly. [S]